Mineralys Therapeutics, Inc.
NMS: MLYSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Mineralys Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MLYS Z-Score →About Mineralys Therapeutics, Inc.
Healthcare
Biotechnology
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
📊 Fundamental Analysis
Mineralys Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -36.9%, which indicates that capital utilization is currently under pressure.
At a current price of $26.62, MLYS currently sits at the 40th percentile of its 52-week range (Range: $12.59 - $47.65).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$2.19B
Trailing P/E
--
Forward P/E
-14.55
Beta (5Y)
0.69
52W High
$47.65
52W Low
$12.59
Avg Volume
1.24M
Day High
Day Low